To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid improves survival in myeloma Phase III

Celgene Corp. (NASDAQ:CELG) said updated data from the Phase III CALGB-100104 trial in newly diagnosed

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE